The FDA recently issued a broad safety communication regarding the possible increased risk of osteoporosis-related bone fracture with the use of PPI's. PPI's are regularly used in CF for treatment of GORD and to help with the efficiency of PERT. And as osteoporosis is a co-morbidity of CF we aimed to assess if there was any relationship between PPI and bone density in children with CF. Methods: A retrospective review of PPI usage and dxa scans was conducted. Sixtyfour children with mean age of 11 (1.8 SD) were included in study. PPI usage and duration was recorded. Dxa scans were carried out on the Lunar DPXL-PED. Bone mineral density (BMD) was recorded and bone mineral apparent density (BMAD) was calculated. FEV1 was also recorded. Minitab Statistical Package was used to analyse the data. Results: Twenty-two (35%) of children were on PPI's. Duration of use ranged from 1 to 4 years. PPI usage had a marginally significant negative effect on BMD [Z score mean of −0.31 (no PPI) and −0.94 (on PPI), p = 0.05]. PPI had no effect on BMAD [z score of 0.17 (no PPI) and −0.37 (on PPI), p = 0.08]. The duration of PPI had no influence on BMD or BMAD (p = 0.71 and p = 0.51). There was no difference in FEV1 between the two groups (means of 75% and 76%, p = 0.84). Conclusion: PPI's may be prescribed more frequently in sicker patients and thus could explain the marginal difference found between groups. However this is not the case here as FEV1 did not differ. Therefore further larger studies are needed in this area. In the meantime, clinicians should be aware of their potential risk when considering PPI therapy and should use the lowest effective dose and duration necessary. Introduction: While even recent data confirm that osteopenia and osteoporosis are very common in adults with cystic fibrosis (CF), no data are available about bone status in children. Quantitative bone ultrasound (QUS) has been used as a method to identify reduced bone mineral status in children with disturbance of growth or disorders affecting bone health. QUS has also been used in adults with CF showing good specificity.
Introduction: While even recent data confirm that osteopenia and osteoporosis are very common in adults with cystic fibrosis (CF), no data are available about bone status in children. Quantitative bone ultrasound (QUS) has been used as a method to identify reduced bone mineral status in children with disturbance of growth or disorders affecting bone health. QUS has also been used in adults with CF showing good specificity.
Methods:
We performed phalangeal quantitative ultrasound examination in patients with classical CF aged 3 to 6 years and in a group of control. The device used (DBM Sonic, IGEA, Carpi, Modena, Italy), based on the transmission of ultrasound through the proximal phalangeal diaphysis calculates raw data and Z-scores for amplitude-dependent speed of sound (AD-SoS) and bone transmission time (BTT).
Results:
We enrolled 30 patients with CF aged 3 to 6 years (15 males, 15 females, mean age 4.7±1.7 years) and 100 non-CF outpatients (46 males, 54 females, mean age 4.3±1.8 years) coming to hospital for acute events (mainly acute cough). AD-SoS value was similar in both CF and control groups (Z-scores −0.1±1.7 and 0.3±1.1, respectively) whereas BTT was significantly lower in CF group than in control group (Z-scores −0.07±0.8 and 0.24±0.7, respectively, p = 0.05). Conclusion: Although our data need to be supported by larger studies we found significantly lower BTT values in children with cystic fibrosis than in healthy children. In the absence of risk factors for osteoporosis such as diabetes, glucocorticoid use, malnutrition this result may reflect the role of CFTR dysfunction on bone tissue suggesting the need to anticipate the evaluation of bone status in early age. 
